Cost effectiveness of high-dose intravenous esomeprazole for peptic ulcer bleeding.
Peptic ulcer bleeding (PUB) is a serious and sometimes fatal condition. The outcome of PUB strongly depends on the risk of rebleeding. A recent multinational placebo-controlled clinical trial (ClinicalTrials.gov identifier: NCT00251979) showed that high-dose intravenous (IV) esomeprazole, when administered after successful endoscopic haemostasis in patients with PUB, is effective in preventing rebleeding. From a policy perspective it is important to assess the cost efficacy of this benefit so as to enable clinicians and payers to make an informed decision regarding the management of PUB. Using a decision-tree model, we compared the cost efficacy of high-dose IV esomeprazole versus an approach of no-IV proton pump inhibitor for prevention of rebleeding in patients with PUB. The model adopted a 30-day time horizon and the perspective of third-party payers in the USA and Europe. The main efficacy variable was the number of averted rebleedings. Healthcare resource utilization costs (physician fees, hospitalizations, surgeries, pharmacotherapies) relevant for the management of PUB were also determined. Data for unit costs (prices) were primarily taken from official governmental sources, and data for other model assumptions were retrieved from the original clinical trial and the literature. After successful endoscopic haemostasis, patients received either high-dose IV esomeprazole (80 mg infusion over 30 min, then 8 mg/hour for 71.5 hours) or no-IV esomeprazole treatment, with both groups receiving oral esomeprazole 40 mg once daily from days 4 to 30. Rebleed rates at 30 days were 7.7% and 13.6%, respectively, for the high-dose IV esomeprazole and no-IV esomeprazole treatment groups (equating to a number needed to treat of 17 in order to prevent one additional patient from rebleeding). In the US setting, the average cost per patient for the high-dose IV esomeprazole strategy was $US14 290 compared with $US14 239 for the no-IV esomeprazole strategy (year 2007 values). For the European setting, Sweden and Spain were used as examples. In the Swedish setting the corresponding respective figures were Swedish kronor (SEK)67 862 ($US9220 at average 2006 interbank exchange rates) and SEK67 807 ($US9212) [year 2006 values]. Incremental cost-effectiveness ratios were $US866 and SEK938 ($US127), respectively, per averted rebleed when using IV esomeprazole. For the Spanish setting, the high-dose IV esomeprazole strategy was dominant (more effective and less costly than the no-IV esomeprazole strategy) [year 2008 values]. All results appeared robust to univariate/threshold sensitivity analysis, with high-dose IV esomeprazole becoming dominant with small variations in assumptions in the US and Swedish settings, while remaining a dominant approach in the Spanish scenario across a broad range of values. Sensitivity variables with prespecified ranges included lengths of stay and per diem assumptions, rebleeding rates and, in some cases, professional fees. In patients with PUB, high-dose IV esomeprazole after successful endoscopic haemostasis appears to improve outcomes at a modest increase in costs relative to a no-IV esomeprazole strategy from the US and Swedish third-party payer perspective. Whereas, in the Spanish setting, the high-dose IV esomeprazole strategy appeared dominant, being more effective and less costly.
Division of Gastroenterology, McGill University Health Centre, Montreal General Hospital, Montreal, Quebec, Canada. alan.barkun@muhc.mcgill.ca
Alan N
AN
Barkun
Viviane
V
Adam
Joseph J Y
JJ
Sung
Ernst J
EJ
Kuipers
Joachim
J
Mössner
Dennis
D
Jensen
Robert
R
Stuart
James Y
JY
Lau
Emma
E
Nauclér
Jan
J
Kilhamn
Helena
H
Granstedt
Bengt
B
Liljas
Tore
T
Lind
D000284:Administration, Oral; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000191:economics*; D003131:Combined Modality Therapy / Q000191:economics; D003362:Cost-Benefit Analysis / Q000379:methods / Q000706:statistics & numerical data*; D003661:Decision Support Techniques; D064098:Esomeprazole / Q000008:administration & dosage / Q000191:economics*; D017048:Health Care Costs / Q000706:statistics & numerical data*; D016558:Hemostasis, Endoscopic / Q000191:economics; D006801:Humans; D007262:Infusions, Intravenous; D018803:Models, Economic; D010438:Peptic Ulcer Hemorrhage / Q000188:drug therapy* / Q000191:economics* / Q000517:prevention & control / Q000628:therapy; D016032:Randomized Controlled Trials as Topic; D013030:Spain; D013548:Sweden; D016896:Treatment Outcome; D014481:United States
D000897:Anti-Ulcer Agents; D064098:Esomeprazole